Brokerage Firm Rating on Mylan N.V. (MYL)

Mylan N.V. (MYL) : The consensus on Mylan N.V. (MYL) based on 10 analyst recommendation on the company stock is 2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Mylan N.V. (MYL) : Average target price received by Mylan N.V. (MYL) is $59 with an expected standard deviation of $7.21. The most aggressive target on the stock is $70, whereas the most downbeat target is $51. 7 financial analysts are currently covering the stock.


For the current week, the company shares have a recommendation consensus of Buy. Mylan N.V. (NASDAQ:MYL): The stock opened at $49.09 on Thursday but the bulls could not build on the opening and the stock topped out at $49.40 for the day. The stock traded down to $48.56 during the day, due to lack of any buying support eventually closed down at $48.71 with a loss of -0.16% for the day. The stock had closed at $48.79 on the previous day. The total traded volume was 3,496,756 shares.

In a related news, Maroon Joseph C Md, director of Mylan N.V., had purchased 1,670 shares on June 3, 2016. The total value of the transaction was $75,067. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.